InvestSMART

Invion Limited (ASX:IVX)

ALERT: Price-sensitive ASX Announcement for IVX
Current share price for IVX : $0.037 -0.014 (-27.45%)+
Announcement
Release
19 May 2026 9:21AM
Price at Release
$0.051
Full Release
download
Summary
Invion Limited has entered into a strategic partnership with SANGMYUNG Innovation Co., Ltd. to explore the application of its Photosoft™ platform technology, a next-generation photodynamic therapy (PDT), for treating retinal vascular diseases, including wet age-related macular degeneration (wet AMD). This collaboration marks Invion's first venture into the ophthalmology sector, aiming to address the unmet medical needs in treatment options for wet AMD. SANGMYUNG will fund and conduct preclinical efficacy studies utilizing select compounds from Invion's library of Photosoft photosensitisers. Invion will supply the compounds and retain all intellectual property rights, while SANGMYUNG, equipped with its proprietary drug delivery devices, aims to enhance drug delivery directly to the suprachoroidal space of the eye. The global market for wet AMD is projected to grow significantly, driven by an aging population and the need for new therapies beyond current anti-VEGF options.
Key Points
  • Partnership with SANGMYUNG to explore Photosoft for eye diseases.
  • Focus on wet age-related macular degeneration treatment.
  • SANGMYUNG to conduct and fund preclinical studies.
  • Invion retains all rights to the Photosoft technology.
  • Collaboration aims to address unmet needs in wet AMD treatment.
  • Potential for Photosoft to offer alternative to anti-VEGF therapies.
  • Global wet AMD market expected to grow significantly by 2032.
  • Photosoft compounds may overcome current treatment limitations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.